Shah Ravi V, Januzzi James L
Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.
Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.
Clin Lab Med. 2014 Mar;34(1):87-97, vi-vii. doi: 10.1016/j.cll.2013.11.009. Epub 2014 Jan 14.
Circulating biomarkers that directly reflect disease progression, hemodynamics, and ventricular remodeling at a molecular level are critical to risk stratification in heart failure (HF), affording unique insights into pathophysiology not fully captured by traditional risk markers. Despite the wealth of data confirming the importance of natriuretic peptides in HF diagnosis and prognosis, residual clinical risk in HF suggests that additional biomarkers complementary to natriuretic peptides may be useful. In this article, the current literature addressing the role of these biomarkers in the clinical diagnosis and risk stratification in HF is summarized.
在分子水平上直接反映疾病进展、血流动力学和心室重塑的循环生物标志物对于心力衰竭（HF）的风险分层至关重要，它能提供传统风险标志物无法完全捕捉到的独特病理生理学见解。尽管有大量数据证实利钠肽在HF诊断和预后中的重要性，但HF患者仍存在临床残余风险，这表明补充利钠肽的其他生物标志物可能有用。本文总结了当前关于这些生物标志物在HF临床诊断和风险分层中作用的文献。
